» Articles » PMID: 15833835

Gene Expression Profiling Allows Distinction Between Primary and Metastatic Squamous Cell Carcinomas in the Lung

Overview
Journal Cancer Res
Specialty Oncology
Date 2005 Apr 19
PMID 15833835
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Lung neoplasms commonly develop in patients previously treated for head and neck carcinomas. The derivation of these tumors, either as new primary lung cancers or as metastatic head and neck cancers, is difficult to establish based on clinical or histopathologic criteria since both are squamous cell carcinomas and have identical features under light microscopy. However, this distinction has significant treatment and prognostic implications. Gene expression profiling was performed on a panel of 52 sequentially collected patients with either primary lung (n = 21) or primary head and neck (n = 31) carcinomas using the Affymetrix HG_U95Av2 high-density oligonucleotide microarray. Unsupervised hierarchical clustering with Ward linkage and the Pearson correlation metric was performed. To assess robustness, bootstrap resampling was performed with 1,000 iterations. A t test of the normalized values for each gene was used to determine the genes responsible for segregating head and neck from lung primary carcinomas, and those with the most differential expression were used for later analyses. In the absence of a large "test" set of tumors, we used a supervised leave-one-out cross-validation to test how well we could predict the tumor origin. Once a gene expression profile was established, 12 lung lesions taken from patients with previously treated head and neck cancers were similarly analyzed by gene expression profiling to determine their sites of origin. Unsupervised clustering analysis separated the study cohort into two distinct groups which reliably remained segregated with bootstrap resampling. Group 1 consisted of 30 tongue carcinomas. Group 2 consisted of 21 lung cancers and 1 tongue carcinoma. The clustering was not changed even when normal lung or tongue profiles were subtracted from the corresponding carcinomatous lesions, and a leave-one-out cross-validation showed a 98% correct prediction (see Supplementary Data 1). A minimum set of 500 genes required to distinguish these groups was established. Given the ability to segregate these lesions using molecular profiling, we analyzed the lung tumors of undetermined origin. All cases clearly clustered with either lung or tongue tumor subsets, strongly supporting our hypothesis that this technique could elucidate the tissue of origin of metastatic lesions. Although histologically similar, squamous cell carcinomas have distinct gene expression profiles based on their anatomic sites of origin. Accordingly, the application of gene expression profiling may be useful in identifying the derivation of lung nodules and consequently enhances treatment planning.

Citing Articles

CAVIN2/SDPR Functioned as a Tumor Suppressor in Lung Adenocarcinoma from Systematic Analysis of Caveolae-Related Genes and Experimental Validation.

Zhu K, Wang B, Li Y, Yu Y, Chen Z, Yue H J Cancer. 2023; 14(11):2001-2014.

PMID: 37497407 PMC: 10367915. DOI: 10.7150/jca.84567.


High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation.

Liu L, Xie B, Zhu W, He Q, Zhou J, Liu S Oncol Res. 2023; 31(3):275-286.

PMID: 37305382 PMC: 10229306. DOI: 10.32604/or.2023.028227.


The High Expression of Minichromosome Maintenance Complex Component 5 Is an Adverse Prognostic Factor in Lung Adenocarcinoma.

Sun M, Wang T, Zhu Y, Zhang Y, Zhu L, Li X Biomed Res Int. 2022; 2022:4338793.

PMID: 35360518 PMC: 8961428. DOI: 10.1155/2022/4338793.


Bioinformatic analysis of PLOD family member expression and prognostic value in non-small cell lung cancer.

Qi Q, Huang W, Zhang H, Zhang B, Sun X, Ma J Transl Cancer Res. 2022; 10(6):2707-2724.

PMID: 35116582 PMC: 8798377. DOI: 10.21037/tcr-21-73.


Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non-Small-Cell Lung Cancer Patients.

Durslewicz J, Klimaszewska-Wisniewska A, Jozwicki J, Antosik P, Smolinska-Switala M, Gagat M Cancer Control. 2021; 28:10732748211056697.

PMID: 34818944 PMC: 8640983. DOI: 10.1177/10732748211056697.